RxDoctor Payments Data

Thilina Marasinghe, MD

Internal Medicine · San Antonio, TXNPI 1821160938

Payments from drug & device makers

$767in general payments, 2019–2025

Across 10 payments — averaging $76.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$238
  • Portola Pharmaceuticals, LLC$125
  • Biogen$125
  • Dova Pharmaceuticals$123
  • Gilead$79
  • Pfizer$39
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$767100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$767 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$47,052
Medicare patients
219
Services billed
654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin104$183,475
MounjaroTirzepatide70$101,504
EliquisApixaban84$100,472
FarxigaDapagliflozin Propanediol52$83,929
RybelsusSemaglutide41$83,274
TrulicityDulaglutide34$67,981
OzempicSemaglutide36$44,560
MyrbetriqMirabegron49$44,181
JanuviaSitagliptin Phosphate24$37,930
XareltoRivaroxaban17$27,264
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$14,064
Spiriva HandihalerTiotropium Bromide17$13,684
SymbicortBudesonide/Formoterol Fumarate24$8,149
Lantus SolostarInsulin Glargine,hum.Rec.Anlog65$7,861
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen164$7,548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$100,47284 claims
AstraZenecaFarxiga, Symbicort$238$92,07976 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →